| Symbol | MDGL |
|---|---|
| Name | MADRIGAL PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 200 BARR HARBOR DRIVE,SUITE 200, FOUR TOWER BRIDGE, WEST CONSHOHOCKEN, Pennsylvania, 19428, United States |
| Telephone | +1 267 824-2827 |
| Fax | — |
| — | |
| Website | https://www.madrigalpharma.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001157601 |
| Description | Madrigal Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and non-alcoholic steatohepatitis (NASH). The product portfolio of the company includes MGL-3196, an orally administered, small-molecule liver-directed B-selective THR agonist, which is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. Also, MGL-3196 reduces triglycerides in the plasma and liver by increasing fat metabolism and shows an anti-diabetic action. Additional info from NASDAQ: |
Soergel David 🔴 sold 844 shares of MADRIGAL PHARMACEUTICALS, INC. (MDGL) at $515.90 Transaction Date: May 18, 2026 | Filing ID: 036078
Read more📋 David Soergel (Officer) plans to sell 844 shares of Madrigal Pharmaceuticals, Inc. (at $523.69 each, total $442K) Filed: May 18, 2026 | ID: 036075
Read moreNew Form SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001013594-26-000612 <b>Size:</b> 8 KB
Read moreNew Form SCHEDULE 13G/A - MADRIGAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001274173-26-000142 <b>Size:</b> 12 KB
Read more(10% Negative) MADRIGAL PHARMACEUTICALS, INC. (MDGL) Announces Delay in mutation Trials for 4Q26 •Reports cash Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreMadrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates
Read more(50% Neutral) MADRIGAL PHARMACEUTICALS, INC. (MDGL) Announces New Board Appointment
Read moreNew Form ARS - MADRIGAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050364 <b>Size:</b> 877 KB
Read moreNew Form DEFA14A - MADRIGAL PHARMACEUTICALS, INC. <b>Filed:</b> 2026-04-28 <b>AccNo:</b> 0001104659-26-050349 <b>Size:</b> 297 KB
Read moreMadrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT07541469 | Rezdiffra Pregnancy and Lactation Registry | — | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 2026-03-04 | 2030-04-08 | ClinicalTrials.gov |
| NCT07335601 | Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH | Phase2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | Recruiting | 2025-12-29 | 2027-12-01 | ClinicalTrials.gov |
| NCT06397872 | A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Multiple … | Phase1 | Renal Impairment | Completed | 2024-03-06 | 2024-12-31 | ClinicalTrials.gov |
| NCT05500222 | A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Pa… | Phase3 | NASH | Active_Not_Recruiting | 2022-08-26 | 2027-01-01 | ClinicalTrials.gov |
| NCT04951219 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in P… | Phase3 | Non-Alcoholic Fatty Liver Disease | Active_Not_Recruiting | 2021-07-09 | 2026-04-01 | ClinicalTrials.gov |
| NCT04197479 | A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in N… | Phase3 | Non-Alcoholic Fatty Liver Disease | Completed | 2019-12-16 | 2023-01-06 | ClinicalTrials.gov |
| NCT04671069 | Drug Interaction Study of MGL-3196 With Clopidogrel | Phase1 | Healthy | Completed | 2019-07-26 | 2019-09-14 | ClinicalTrials.gov |
| NCT03900429 | A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in… | Phase3 | NASH - Nonalcoholic Steatohepatitis | Active_Not_Recruiting | 2019-03-28 | 2028-01-01 | ClinicalTrials.gov |
| NCT04671056 | Drug Interaction Study of MGL-3196 With Pioglitazone | Phase1 | Healthy | Completed | 2018-11-09 | 2019-01-05 | ClinicalTrials.gov |
| NCT04643795 | Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Mul… | Phase1 | Hepatic Impairment | Completed | 2018-10-25 | 2021-08-04 | ClinicalTrials.gov |
| NCT03413124 | Bioavailability Study of MGL-3196 Tablets Compared to Capsules | Phase1 | Healthy | Completed | 2018-02-05 | 2018-03-13 | ClinicalTrials.gov |
| NCT03220165 | Radiolabeled Study to Determine the Mass Balance of [14C] MGL-3196 | Phase1 | Healthy | Completed | 2017-08-06 | 2017-09-03 | ClinicalTrials.gov |
| NCT03038022 | Study of MGL-3196 in Patients With Heterozygous Familial Hypercholesterolemia (… | Phase2 | Heterozygous Familial Hypercholesterolemia | Completed | 2017-02-23 | 2018-01-15 | ClinicalTrials.gov |
| NCT02912260 | Phase 2 Study of MGL-3196 in Patients With Non-Alcoholic Steatohepatitis (NASH) | Phase2 | Non-alcoholic Steatohepatitis | Completed | 2016-10-18 | 2021-11-23 | ClinicalTrials.gov |
| NCT02749578 | Drug Interaction Study of MGL-3196 With Atorvastatin | Phase1 | Healthy | Completed | 2016-04-01 | 2016-05-01 | ClinicalTrials.gov |
| NCT02542969 | Drug Interaction Study of MGL-3196 With Rosuvastatin and Simvastatin | Phase1 | Healthy | Completed | 2015-09-01 | 2015-10-01 | ClinicalTrials.gov |
| NCT01519531 | Ascending Multiple-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Phase1 | Drug Safety | Completed | 2012-01-01 | 2012-11-01 | ClinicalTrials.gov |
| NCT01367873 | Ascending Single-Dose Study to Evaluate VIA-3196 in Healthy Subjects | Phase1 | Drug Safety | Completed | 2011-06-01 | 2011-10-01 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| VIA-3196 | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01519531 |
| Placebo | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01519531 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02749578 |
| Atorvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02749578 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03220165 |
| MGL-3196 Capsule | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| MGL-3196 Tablet | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| Pioglitazone 15mg | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671056 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671056 |
| Clopidogrel | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| MGL-3196 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| Rosuvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| Simvastatin | Other | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| VIA-3196 | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01367873 |
| Placebo | Other | Phase PHASE1 | Drug Safety | COMPLETED | NCT01367873 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04197479 |
| Placebo | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | COMPLETED | NCT04197479 |
| MGL-3196 | Other | Phase PHASE1 | Hepatic Impairment | COMPLETED | NCT04643795 |
| Liver Biopsy | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 | Other | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| Placebo | Other | Phase PHASE3 | NASH | ACTIVE_NOT_RECRUITING | NCT05500222 |
| Resmetirom | Other | Phase PHASE3 | NASH | ACTIVE_NOT_RECRUITING | NCT05500222 |
| Resmetirom | Other | Phase PHASE3 | Non-Alcoholic Fatty Liver Disease | ACTIVE_NOT_RECRUITING | NCT04951219 |
| 100 mg Resmetirom Tablet | Other | Phase PHASE1 | Renal Impairment | COMPLETED | NCT06397872 |
| Placebo | Other | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| MGL-3196 (resmetirom) | Other | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| Placebo | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT02912260 |
| MGL-3196 | Other | Phase PHASE2 | Non-alcoholic Steatohepatitis | COMPLETED | NCT02912260 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Placebo | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Resmetirom | Other | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07335601 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| Rezdiffra | Other | Preclinical | MASH - Metabolic Dysfunction-Associated Steatohepatitis | RECRUITING | NCT07541469 |
| 100 mg Resmetirom Tablet | DRUG | Phase PHASE1 | Renal Impairment | COMPLETED | NCT06397872 |
| Clopidogrel | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| Pioglitazone 15mg | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04671056 |
| Resmetirom | DRUG | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT07335601 |
| Liver Biopsy | PROCEDURE | Phase PHASE3 | NASH - Nonalcoholic Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT03900429 |
| MGL-3196 Capsule | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| MGL-3196 Tablet | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT03413124 |
| MGL-3196 (resmetirom) | DRUG | Phase PHASE2 | Heterozygous Familial Hypercholesterolemia | COMPLETED | NCT03038022 |
| Atorvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02749578 |
| MGL-3196 | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT04671069 |
| Rosuvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| Simvastatin | DRUG | Phase PHASE1 | Healthy | COMPLETED | NCT02542969 |
| VIA-3196 | DRUG | Phase PHASE1 | Drug Safety | COMPLETED | NCT01519531 |
| Placebo | DRUG | Phase PHASE2 | MASH - Metabolic Dysfunction-Associated Steatohepatitis | ACTIVE_NOT_RECRUITING | NCT07335601 |